MyoKardia begins dosing in Phase I trial of MYK-491 to treat DCM

US-based clinical stage biopharmaceutical firm MyoKardia has begun dosing in its Phase I single ascending dose clinical study of MYK-491 to treat dilated cardiomyopathy (DCM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Secondary functional mitral regurgitation (FMR) in patients with non-ischemic dilated cardiomyopathy (NIDCM) is associated with worse prognosis and poor survival,1 and results after mitral valve (MV) surgery are still controversial. The main reason is that FMR is not an intrinsic disease of the valve, but instead it mirrors a ventricular disease. In NIDCM, progressive left ventricular (LV) remodeling causes papillary muscle displacement and mitral annular dilation. Both conditions cause leaflet tethering and reduce leaflet coaptation.
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ADULT – Commentary Source Type: research
AbstractPurpose of reviewIn this review, we will focus the role of CMR in dilated cardiomyopathy and genetic cardiomyopathy.Recent findingsNon-invasive imaging plays a crucial rule in the diagnostic workup of cardiomyopathies. In these entities, echocardiography is the first-line imaging tool for diagnostic assessment, but CMR has the unique capability to identify and differentiate the underlying pathology, mainly through tissue characterization, even if the EF is preserved. Myocardial tissue characterization is crucial for adequate prognostication and guiding of therapy. Visual, semi-quantitative, and quantitative methods...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
CONCLUSIONS Our study used integrated bioinformatic analyses and revealed some important genes in mice with LMNA-related DCM, which could provide novel insights into the mechanism underlying human LMNA-related DCM. PMID: 32581210 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
To study the correlation between single nucleotide polymorphism (SNP) of the 3′ untranslated region (UTR) rs9722 locus in S100B and the risk of chronic heart failure (CHF), plasma levels of S100B protein as well as has-miR-340-3p in a Chinese Han population. A total of 215 patients with CHF (124 ischemic cardiomyopathy (ICM) and 91 dilated cardiomyopathy (DCM)) and 215 healthy controls were recruited to analyze the S100B rs9722 genotype by Sanger sequencing. The levels of hsa-miR-340-3p in the plasma were detected by RT-PCR, and S100B levels were detected by ELISA. The risk of CHF in S100B rs9722 locus T allele car...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
AbstractAimContemporary survival trends in dilated cardiomyopathy (DCM) are largely unknown. The aim of this study is to investigate clinical descriptors, survival trends and the prognostic impact of aetiological characterization in DCM patients.Methods and resultsDilated cardiomyopathy patients were consecutively enrolled and divided into four groups according to the period of enrolment (1978 –1984; 1985–1994; 1995–2004; and 2005–2015). A subset of patients with DCM of specific aetiology, enrolled from 2005 to 2015, was also analysed. Over a mean follow‐up of 12 ± 8 ye...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
We describe a patient presenting with acute heart failure, new cardiomyopathy, refractory hypokalaemia, severe hyperglycaemia, and uncontrolled hypertension who was found to have hypercortisolism secondary to an ectopic adrenocorticotropic hormone ‐secreting primary lung neoplasm. This case highlights the effects of hypercortisolism on the myocardium. The finding of a non‐dilated cardiomyopathy in this case is unique because the majority of previously reported Cushing syndrome cardiomyopathy cases have described left ventricular dilatatio n or significant left ventricular hypertrophy. In addition, small‐cell lung can...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Case Report Source Type: research
Publication date: Available online 20 June 2020Source: Mechanisms of DevelopmentAuthor(s): Yanyan Liu, Ziyuan Lin, Mingfeng Liu, Huijuan Liao, Yan Chen, Xiaohu Zhang, Hsiao Chang Chan, Bin Zhou, Li Rao, Huaqin Sun
Source: Mechanisms of Development - Category: Biology Source Type: research
CONCLUSIONS: This study has shown that two markers - cardiotropic viruses and myocardial inflammation - are prevalent among DCM patients. They are also helpful in identifying sub-groups of DCM. An increased number of T-lymphocytes in the myocardium is a predictor of poor mid-term and long-term prognosis. PMID: 32567670 [PubMed - as supplied by publisher]
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research
Abstract BACKGROUND: Chronic valvular heart disease leads to systolic dysfunction and left atrial enlargement that ultimately results in heart failure. PURPOSE: To investigate prognostic importance of Echocardiography and plasma natriuretic peptide levels that increase as a compensatory response and can be used as predictive markers for cardiac hypertrophy. MATERIAL AND METHODS: The patients were divided into three groups: 51 with left ventricle hypertrophy due to aortic valve disease; 126 with left atrial enlargement due to mitral valve dysfunction; and 76 with both conditions. Atrial natriuretic peptid...
Source: Acta Radiologica - Category: Radiology Authors: Tags: Acta Radiol Source Type: research
In this study we aimed to evaluate management strategies in our pediatric cardiac transplantation candidates with PH and high PVR prior to OHT. METHOD: Twenty-six cardiac transplantation candidates (age: 10.2 ± 4.6, 1-17 years) underwent cardiac catheterization for the determination of PVR and pulmonary arterial pressure. They were admitted to the hospital and received 1-3 days of intravenous (IV) vasodilator therapy; 0.5-3 μg/kg/min nitroglyserin and/or 0.5-3 μg/kg/min nitroprusside, 5-15 μg/kg/min dobutamin and/or dopamin to keep systolic blood pressure above 80 mmHg. RESULTS: Thirteen patients ...
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Tags: Turk J Pediatr Source Type: research
More News: Cardiology | Cardiomyopathy | Dilated Cardiomyopathy | Heart | Pharmaceuticals | Study